Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/fw4ctl/investigation ) ... on China,s Entecavir Market, 2010-2019" report to their ... hepatitis B virus (HBV) exceeds 100 million in ... from chronic Hepatitis B. About 0.5 million Chinese is ... caused by chronic Hepatitis B, causing a loss of ...
(Date:9/3/2015)... , Sep. 03, 2015 ... addition of the "Investigation Report on China,s Raloxifene ... According to the statistics, over 200 million people suffer ... and above in China , 50% ... is 30%-50% among women aged 60 and above. ...
(Date:9/3/2015)... 2015 China,s startup ... Patch, a wearable medical device that can continuously monitor ... providing safety guidance for pregnant women. The device will ... device, which measures 4 centimeters in diameter, is as ... more than an Apple earphone cord. The small and ...
Breaking Medicine Technology:China Entecavir Market Report 2010-2019 2Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2
... (Nasdaq CM: INSM), a biopharmaceutical company, will host a ... AM ET, to discuss its financial results for the ... quarterly financial results press release before the market opens ... the live conference call, please dial 800-901-5213 (U.S. callers) ...
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... 31, 2012, on Thursday, May 10, 2012, following the close ... investor conference call and live webcast to discuss the financial ... Time / 2:00 p.m. Pacific Time on the same date. The ...
Cached Medicine Technology:Insmed to Host 2012 First Quarter Earnings Conference Call 2Insmed to Host 2012 First Quarter Earnings Conference Call 3Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 2Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 3
(Date:9/3/2015)... ... September 03, 2015 , ... While bariatric surgeon Michael Feiz, M.D., ... when preparing for a bariatric procedure, some patients have been recently asking further questions ... instructions typical for many types of surgery that should be followed in the days ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to announce a ... norm not the exception. , St. Jude was recently named one of the nation’s ... making it one of only 10 hospitals in the state to earn the distinction. ...
(Date:9/3/2015)... ... , ... TransPack Toon gives users a set of 90 cartoon transitions for ... in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and many ... features 90 cartoon transitions from 30 unique styles. Editors can choose between line ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Inc. , a privately held medical technology company that will bring low-cost cancer ... markets worldwide. , Preora’s proprietary and automated technology platform detects and measures ...
(Date:9/3/2015)... Buffalo, New York (PRWEB) , ... September 03, 2015 , ... ... We Do”. William Mattar, Esq. believes this does not stop at any certain ... closed captioning to its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , ...
Breaking Medicine News(10 mins):Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2
... A nationwide study examining the safety of Tasers ... safe, causing a low occurrence of serious injuries., This ... associated with Tasers. It is the first injury epidemiology ... assess the overall risk and severity of injuries in ...
... no significant change in the quality of care for ... Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) ... 2007 issue of CANCER, a peer-reviewed journal of the ... Friedman from the Duke Clinical Research Institute in Durham, ...
... -- Cancer patients receiving chemotherapy have not noticed a ... of the Medicare Prescription Drug, Improvement and Modernization Act ... government reimbursement to oncologists, according to a new study ... (DCRI). , Critics of the MMA often said that ...
... - Report Suggests Millions of Sports Persons are Suffering ... health reveals that men and,women who aim to keep fit, ... of all active respondents who took part in the survey ... seem to be a common occurrence for the nations top,sports ...
... recent months, a,perfect storm of new technology and research ... and genetics, writes Lee Silver, a professor,of molecular biology ... heredity is the result of an incredibly complex interplay,among ... different,genes and even the vast stretches of "junk DNA" ...
... today expressed their great disappointment in President Bushs veto ... Health Insurance Program (SCHIP). The sentiment was expressed ... by David C. Dale, MD, FACP, president of the ... the 124,000 internal medicine physicians and medical student members ...
Cached Medicine News:Health News:Nationwide independent Taser study results suggest devices are safe 2Health News:Patients perceived cancer care unaffected by lower Medicare reimbursements 2Health News:Medicare modernization act did not change chemotherapy as feared 2Health News:More Damage Than Good? Shock Survey Reveals Sport can Actually be bad for Your Joints 2Health News:More Damage Than Good? Shock Survey Reveals Sport can Actually be bad for Your Joints 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 4Health News:'Great disappointment' in veto of SCHIP legislation expressed by American College of Physicians 2
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
... Tests are used by hospitals, clinics and ... human health conditions. The majority of these ... which are offered in strip, cassette, and ... through membrane tests are also available. All ...
ELISA kit for detection of the cardiac marker Myoglobin. Kit features interchangeable reagents, E-Z Process performed at room temp, and results in less than 1 hour!...
Medicine Products: